Processa Pharmaceuticals Inc’s filing revealed that its Director Yorke Justin W acquired Company’s shares for reported $9889.0 on Jan 27 ’25. In the deal valued at $0.80 per share,12,400 shares were bought. As a result of this transaction, Yorke Justin W now holds 12,400 shares worth roughly $3100.0.
Then, Ng George K bought 87,200 shares, generating $69,542 in total proceeds. Upon buying the shares at $0.80, the Chief Executive Officer now owns 87,200 shares.
Before that, Young David bought 124,500 shares. Processa Pharmaceuticals Inc shares valued at $99,289 were divested by the Pres. Research & Development at a price of $0.80 per share. As a result of the transaction, Young David now holds 205,405 shares, worth roughly $51351.25.
H.C. Wainwright initiated its Processa Pharmaceuticals Inc [PCSA] rating to a Buy in a research note published on April 25, 2024; the price target was $8.
Price Performance Review of PCSA
On Monday, Processa Pharmaceuticals Inc [NASDAQ:PCSA] saw its stock jump 6.30% to $0.25. Over the last five days, the stock has gained 4.63%. Processa Pharmaceuticals Inc shares have fallen nearly -72.14% since the year began. Nevertheless, the stocks have fallen -88.91% over the past one year. While a 52-week high of $3.10 was reached on 01/06/25, a 52-week low of $0.15 was recorded on 04/17/25. SMA at 50 days reached $0.3659, while 200 days put it at $0.9682.
Levels Of Support And Resistance For PCSA Stock
The 24-hour chart illustrates a support level at 0.2231, which if violated will result in even more drops to 0.2000. On the upside, there is a resistance level at 0.2686. A further resistance level may holdings at 0.2910. The Relative Strength Index (RSI) on the 14-day chart is 39.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0033, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 43.41%. Stochastics %K at 42.16% indicates the stock is a holding.
